University of Manitoba, Faculty of Medicine, Section of Infectious Diseases, 543 - 745 Basic Medical Sciences Building, Winnipeg MB R3E 0J9, Canada.
Expert Opin Pharmacother. 2011 Dec;12(17):2737-50. doi: 10.1517/14656566.2011.633511.
Hospital-acquired pneumonia is a common infection, associated with substantial mortality. Despite the increasing prevalence of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA), approved treatment options for this pathogen are limited.
This article reviews the pharmacokinetics, dosing, preclinical studies and clinical efficacy, and safety of telavancin, with a particular focus on results from trials in nosocomial pneumonia. PubMed and Congress websites were searched for relevant articles published between 2003 and 2010.
Telavancin is a lipoglycopeptide antibiotic with rapid, bactericidal activity against MRSA, and may provide another option for the treatment of nosocomial pneumonia, owing to Gram-positive pathogens.
医院获得性肺炎是一种常见的感染，与大量的死亡率相关。尽管耐甲氧西林金黄色葡萄球菌（MRSA）引起的医院获得性肺炎的患病率不断增加，但这种病原体的治疗方法有限。
本文综述了替拉万星的药代动力学、剂量、临床前研究和临床疗效，以及安全性，尤其侧重于医院获得性肺炎试验的结果。检索了 2003 年至 2010 年期间在 PubMed 和 Congress 网站上发表的相关文章。
替拉万星是一种糖肽类抗生素，对 MRSA 具有快速杀菌活性，由于革兰氏阳性病原体，可能为治疗医院获得性肺炎提供另一种选择。
